Avenue Therapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

License/Supplier Agreements (Details) - USD ($) $ in Millions	1 Months Ended
	Dec. 31, 2019	Oct. 29, 2018	Jun. 17, 2015
Revogenex License [Member]
Contractual Obligation, Maximum Future Payments			$ 3.0
IV Tramadol [Member] \| Fortress [Member]
Payments to Acquire in Process Research and Development			3.0
IV Tramadol [Member] \| Fortress [Member] \| Upfront Payment [Member]
Payments to Acquire in Process Research and Development			2.0
IV Tramadol [Member] \| Fortress [Member] \| Additional Payment [Member]
Payments to Acquire in Process Research and Development			$ 1.0
Polpharma [Member]
Payments to Acquire in Process Research and Development		$ 2.0
New Drug Application [Member] \| Revogenex License [Member]
Payments to Acquire in Process Research and Development	$ 1.0